BTS Antibody
Description
BTS Antibody in Renal Cell Carcinoma (BST2/CD317)
BST2 (Bone Marrow Stromal Cell Antigen 2), also termed BTS-2 or HM1.24, is a transmembrane protein implicated in cancer progression. Studies on renal cell carcinoma (RCC) reveal its role in tumor growth and invasiveness.
Key Research Findings
-
Expression Analysis:
Immunohistochemical analysis of 123 RCC cases showed 32% BST2 positivity, correlating with advanced tumor stage .
| Parameter | BST2-Positive Cases | BST2-Negative Cases |
|---|---|---|
| Tumor stage (III/IV) | 68% | 32% |
| 5-year survival rate | 48% | 72% |
| Metastasis incidence | 41% | 18% |
-
Functional Impact:
siRNA-mediated BST2 suppression in RCC cell lines (e.g., Caki-1) reduced:
Mechanistic Insights
BST2 enhances cell adhesion and activates ERK/AKT signaling pathways, promoting metastasis .
BTS Antibody in Transplantation Guidelines
The British Transplantation Society (BTS) provides guidelines for detecting and managing donor-specific antibodies (DSAs) in solid organ transplantation .
Clinical Recommendations
Impact of DSAs
-
Antibody-Mediated Rejection (AMR): DSAs targeting HLA class I/II increase AMR risk by 4–7× .
-
Graft Survival: Pre-transplant DSAs reduce 5-year kidney graft survival from 90% to 65% .
Data Synthesis
The term "BTS Antibody" lacks a singular definition but intersects two domains:
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
- The Arabidopsis thaliana BTS paralogs, BTS LIKE1 (BTSL1) and BTS LIKE2 (BTSL2), function redundantly as negative regulators of the iron deficiency response. PMID: 28620661
- This protein mediates the iron response by targeting basic helix-loop-helix transcription factors. PMID: 25452667
